Boston Scientific’s (NYSE:BSX) subsidiary sells 50% of its Zytiga-related royalties to Ontario Municipal Employees Retirement System for $256M.
The sale doesn’t change the company’s 2019 forecast.
BSX gained the Zytiga royalty interests through its acquisition of BTG, which closed in August.
Boston Scientific plans to use the cash to pay down its debt.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.